It is an honor to Omics announce the availability of our ELISA test INNOVATIO ND2. The FIRST ELISA test in the world for the diagnostic and risk, identification of developing Diabetic Nephropathy (DN) in type 2 Diabetes patients.
It represents the first test for this condition, with this dual property of being Diagnostic and Prognostic at the same time.
Type 2 Diabetes is seen as one the main pandemic levels disease of 21st century, and Renal Disease is highly linked to this condition, in fact, Diabetic Nephropathy (ND) could be the most devastating and expensive complication of Type 2 Diabetes based on the need of Dialysis and the costs associated with such treatments.
¿What is innovatio ND2?
It is an honor for Omics to announce the availability of INNOVATIO ND2 ™.
The FIRST ELISA test in the world for the diagnosis and identification of risk of developing diabetic nephropathy (DN) in patients with type 2 diabetes with the dual property of providing diagnostic and prognostic risk measurements at the same time
Type 2 diabetes is considered one of the major pandemic-level diseases of the 21st century, and kidney disease is closely related to this condition, in fact, diabetic nephropathy (DN) is considered the most devastating and costly complication of type diabetes 2 due to its link to dialysis and its impact in patients and families around the world.